+

WO2007044321A3 - Procytotoxines latentes et utilisations de celles-ci - Google Patents

Procytotoxines latentes et utilisations de celles-ci Download PDF

Info

Publication number
WO2007044321A3
WO2007044321A3 PCT/US2006/038584 US2006038584W WO2007044321A3 WO 2007044321 A3 WO2007044321 A3 WO 2007044321A3 US 2006038584 W US2006038584 W US 2006038584W WO 2007044321 A3 WO2007044321 A3 WO 2007044321A3
Authority
WO
WIPO (PCT)
Prior art keywords
disclosed
procytotoxins
compositions
methods
latent
Prior art date
Application number
PCT/US2006/038584
Other languages
English (en)
Other versions
WO2007044321A2 (fr
Inventor
Thomas E Wagner
Xianzhang Yu
Original Assignee
Greenville Hospital System
Thomas E Wagner
Xianzhang Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenville Hospital System, Thomas E Wagner, Xianzhang Yu filed Critical Greenville Hospital System
Priority to JP2008534617A priority Critical patent/JP2009510166A/ja
Priority to AU2006302587A priority patent/AU2006302587A1/en
Priority to CA002624802A priority patent/CA2624802A1/fr
Priority to EP06825387A priority patent/EP1943350A4/fr
Publication of WO2007044321A2 publication Critical patent/WO2007044321A2/fr
Publication of WO2007044321A3 publication Critical patent/WO2007044321A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procytotoxines comprenant un peptide associé à la latence et un peptide cytotoxique, un site de clivage protéolytique étant prévu entre le peptide associé à la latence et le peptide cytotoxique. L'invention concerne également des compositions et des procédés permettant de détruire de manière sélective une cellule cible et des compositions et des méthodes de traitement du cancer chez un patient. L'invention concerne enfin des compositions et des procédés permettant de conférer une latence à une cytotoxine.
PCT/US2006/038584 2005-10-04 2006-09-29 Procytotoxines latentes et utilisations de celles-ci WO2007044321A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2008534617A JP2009510166A (ja) 2005-10-04 2006-09-29 潜伏性プロサイトトキシンおよびそれらの用途
AU2006302587A AU2006302587A1 (en) 2005-10-04 2006-09-29 Latent procytotoxins and uses thereof
CA002624802A CA2624802A1 (fr) 2005-10-04 2006-09-29 Procytotoxines latentes et utilisations de celles-ci
EP06825387A EP1943350A4 (fr) 2005-10-04 2006-09-29 Procytotoxines latentes et utilisations de celles-ci

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72351105P 2005-10-04 2005-10-04
US60/723,511 2005-10-04

Publications (2)

Publication Number Publication Date
WO2007044321A2 WO2007044321A2 (fr) 2007-04-19
WO2007044321A3 true WO2007044321A3 (fr) 2007-07-05

Family

ID=37943314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038584 WO2007044321A2 (fr) 2005-10-04 2006-09-29 Procytotoxines latentes et utilisations de celles-ci

Country Status (5)

Country Link
EP (1) EP1943350A4 (fr)
JP (1) JP2009510166A (fr)
AU (1) AU2006302587A1 (fr)
CA (1) CA2624802A1 (fr)
WO (1) WO2007044321A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632633A (zh) * 2016-11-24 2017-05-10 浙江海洋大学 一种绿侧花海葵抗肿瘤寡肽及其用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004694A1 (fr) * 2012-06-26 2014-01-03 Massachusetts Institute Of Technology Dissimulation réversible de protéines formant des pores pour distribution macromoléculaire
CN103275911B (zh) * 2013-01-02 2015-11-25 温州医学院 一种含有pET-28a(+)-protein400重组质粒的大肠杆菌及其制备方法
CA2917056C (fr) * 2013-06-27 2020-03-24 Rutgers, The State University Of New Jersey Traitement et diagnostic d'une maladie oculaire
US20240082350A1 (en) * 2019-10-11 2024-03-14 Linnane Pharma Ab Vibrio cholerae protein for use against cancer
CN112724258A (zh) * 2019-10-29 2021-04-30 深圳市第二人民医院 靶向杀死癌细胞的复合多肽分子及其制备方法
JP2023534300A (ja) * 2020-07-17 2023-08-08 ジ ユニバーシティ オブ ウェスタン オーストラリア 癌の処置のための組成物および方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942853B2 (en) * 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942853B2 (en) * 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOLLE L. ET AL.: "A Matrix Metalloproteinase 2 Cleavable Melittin/Avidin Conjugate Specifically Targets Tumor Cells in vitro and in vivo", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 22, 2003, pages 93 - 98, XP003015172 *
POTRICH C. ET AL.: "Cytotoxic Activity of a Tumor Protease Activated Pore-Forming Toxin", BIOCONJUGATE CHEMISTRY, vol. 16, March 2005 (2005-03-01) - April 2005 (2005-04-01), pages 369 - 376, XP003013256 *
See also references of EP1943350A4 *
WARREN P. ET AL.: "In Vitro Targeted Killing of Prostrate Tumor Cells by a Synthetic Amoebapore Helix 3 Peptide Modified with Two-Linked Glutamate Residues at the COOH Terminus", CANCER RESEARCH, vol. 61, 15 September 2001 (2001-09-15), pages 6783 - 6787, XP001031416 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632633A (zh) * 2016-11-24 2017-05-10 浙江海洋大学 一种绿侧花海葵抗肿瘤寡肽及其用途
CN106632633B (zh) * 2016-11-24 2020-03-20 浙江海洋大学 一种绿侧花海葵抗肿瘤寡肽及其用途

Also Published As

Publication number Publication date
WO2007044321A2 (fr) 2007-04-19
AU2006302587A1 (en) 2007-04-19
JP2009510166A (ja) 2009-03-12
CA2624802A1 (fr) 2007-04-19
EP1943350A4 (fr) 2009-06-17
EP1943350A2 (fr) 2008-07-16

Similar Documents

Publication Publication Date Title
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
WO2008058239A3 (fr) Spink1 en tant que marqueur du cancer de la prostate et ses utilisations
WO2006127900A3 (fr) Tl1a dans le traitement de maladie
WO2007011693A3 (fr) Compositions de cellules souches derivees du placenta, utilisees dans le traitement de cancers
WO2008070593A3 (fr) Agents se liantà des cibles variables et utilisations de ceux-ci
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
WO2007005941A3 (fr) Conjugues cibles sur le foie
WO2007081879A3 (fr) Méthodes pour prévenir et traiter des métastases de cancer et des pertes osseuses associées à des métastases de cancer
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2007044321A3 (fr) Procytotoxines latentes et utilisations de celles-ci
UA105210C2 (ru) Противораковая вакцина и ее применение
WO2007061939A3 (fr) Dérivés de métabolites de l'inhibiteur de hdac fk228
WO2007047608A3 (fr) Substances therapeutiques ciblees sur la fibrine
WO2007067828A3 (fr) Mimétiques et polypeptides de glp-2, compositions, méthodes et utilisations
WO2008013966A3 (fr) Utilisation de 8-quinolinol et de ses analogues pour cibler des cellules souches cancéreuses
WO2008063768A3 (fr) Compositions et procédés pour traiter des maladies métaboliques
WO2008112290A3 (fr) Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire
WO2007100920A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2006102375A3 (fr) Methodes pour eviter un oedeme dans le traitement ou la prevention de maladies sensibles a ppar$g(g), telles que le cancer
WO2007089902A3 (fr) Compositions et procedes pour favoriser la cicatrisation de tissus d'organismes multicellulaires
WO2007025229A3 (fr) Compositions et utilisations contre hsp27
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
WO2006116185A3 (fr) Procedes destines au traitement de myelomes multiples

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2624802

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008534617

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006825387

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006302587

Country of ref document: AU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载